NHS England Trials Groundbreaking AI Tool to Slash Prostate Cancer Diagnosis Wait Times
London, UK – Men facing the anxious wait for prostate cancer test results could soon receive answers in days rather than weeks, thanks to a pioneering artificial intelligence system now being trialled across England.
The new AI tool, part of a £14 million national project, analyses MRI scans in seconds to spot suspicious lesions that may indicate prostate cancer. Scans flagged as high-risk are immediately escalated to the front of the radiologist queue, and in many cases patients can be offered a biopsy on the same day.
If the trial proves successful, thousands of men could avoid the prolonged uncertainty that currently accompanies suspected prostate cancer, allowing those with the disease to start treatment far sooner.
How the AI changes the pathway
Under the existing system, men referred with raised PSA (prostate-specific antigen) blood test results – which can be elevated for reasons other than cancer – are supposed to receive an MRI scan within days and, if needed, a biopsy shortly afterwards. In practice, heavy radiologist workloads frequently cause delays of several weeks.
The new AI acts as an ultra-fast “second pair of eyes”. It instantly categorises each scan as low, medium, or high risk. Low-risk cases can be safely discharged with reassurance, while high-risk scans trigger same-day clinical review and potential biopsy booking.
“This has the potential to transform the diagnostic pathway,” an NHS England spokesperson said. “Men will no longer have to endure weeks of worry waiting for results when, in many cases, we can tell them much sooner whether they need further tests or treatment.”
Scale of the trial and the disease
The technology will be tested on 10,000 MRI scans at multiple hospital trusts across England. If the results meet safety and accuracy targets, NHS England has signalled it will roll the system out nationwide.
Prostate cancer remains the most common cancer in men in England, with more than 56,000 new cases diagnosed annually. Across the European Union, roughly one in eleven men will be diagnosed with the disease in their lifetime. Although survival rates are high when caught early – over 90% of men survive for ten years or more if diagnosed at stage 1 or 2 – delays in diagnosis and treatment can allow the cancer to spread and become harder to treat.
Reducing unnecessary anxiety
Perhaps equally important is the psychological impact. Many men with raised PSA levels ultimately prove not to have cancer, yet the weeks spent waiting for scans and results can cause significant distress.
“Anything that shortens that period of uncertainty is hugely welcome,” said Laura Kerby, Chief Executive of Prostate Cancer UK. “Faster, smarter diagnosis means men with cancer start treatment sooner, and men without cancer get peace of mind much more quickly.”
The trial forms part of a broader NHS drive to harness artificial intelligence to clear backlogs, improve early detection, and deliver more efficient care. Early results from similar AI tools used in breast and lung cancer screening have already shown substantial reductions in waiting times and improved detection rates.
If the prostate cancer trial mirrors those successes, England could soon set a new standard for rapid cancer diagnosis – offering hope not only to the tens of thousands of men diagnosed each year, but to every man who faces that initial, worrying blood test result.
